Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.09
LZAGY's Cash to Debt is ranked lower than
56% of the 296 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.73 vs. LZAGY: 0.09 )
LZAGY' s 10-Year Cash to Debt Range
Min: 0.07   Max: No Debt
Current: 0.09

Equity to Asset 0.33
LZAGY's Equity to Asset is ranked higher than
53% of the 287 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.60 vs. LZAGY: 0.33 )
LZAGY' s 10-Year Equity to Asset Range
Min: 0.3   Max: 0.5
Current: 0.33

0.3
0.5
F-Score: 7
Z-Score: 2.10
M-Score: -2.62
WACC vs ROIC
8.90%
8.62%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 11.62
LZAGY's Operating margin (%) is ranked higher than
86% of the 292 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.24 vs. LZAGY: 11.62 )
LZAGY' s 10-Year Operating margin (%) Range
Min: 7.06   Max: 15.02
Current: 11.62

7.06
15.02
Net-margin (%) 6.51
LZAGY's Net-margin (%) is ranked higher than
83% of the 292 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.46 vs. LZAGY: 6.51 )
LZAGY' s 10-Year Net-margin (%) Range
Min: 2.43   Max: 14.27
Current: 6.51

2.43
14.27
ROE (%) 11.23
LZAGY's ROE (%) is ranked higher than
86% of the 272 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.91 vs. LZAGY: 11.23 )
LZAGY' s 10-Year ROE (%) Range
Min: 4.11   Max: 22.47
Current: 11.23

4.11
22.47
ROA (%) 3.66
LZAGY's ROA (%) is ranked higher than
82% of the 299 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.48 vs. LZAGY: 3.66 )
LZAGY' s 10-Year ROA (%) Range
Min: 1.3   Max: 7.45
Current: 3.66

1.3
7.45
ROC (Joel Greenblatt) (%) 11.04
LZAGY's ROC (Joel Greenblatt) (%) is ranked higher than
78% of the 298 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.80 vs. LZAGY: 11.04 )
LZAGY' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 7.38   Max: 46.01
Current: 11.04

7.38
46.01
Revenue Growth (3Y)(%) 10.30
LZAGY's Revenue Growth (3Y)(%) is ranked higher than
84% of the 210 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.60 vs. LZAGY: 10.30 )
LZAGY' s 10-Year Revenue Growth (3Y)(%) Range
Min: -5.5   Max: 12.8
Current: 10.3

-5.5
12.8
EBITDA Growth (3Y)(%) 10.20
LZAGY's EBITDA Growth (3Y)(%) is ranked higher than
82% of the 188 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.30 vs. LZAGY: 10.20 )
LZAGY' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -12.4   Max: 48.1
Current: 10.2

-12.4
48.1
EPS Growth (3Y)(%) 15.20
LZAGY's EPS Growth (3Y)(%) is ranked higher than
89% of the 179 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.60 vs. LZAGY: 15.20 )
LZAGY' s 10-Year EPS Growth (3Y)(%) Range
Min: -32.9   Max: 29.6
Current: 15.2

-32.9
29.6
» LZAGY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with LZAGY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 30.10
LZAGY's P/E(ttm) is ranked higher than
88% of the 340 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. LZAGY: 30.10 )
LZAGY' s 10-Year P/E(ttm) Range
Min: 8.61   Max: 69.7
Current: 30.1

8.61
69.7
Forward P/E 1.78
LZAGY's Forward P/E is ranked higher than
99% of the 340 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. LZAGY: 1.78 )
N/A
PE(NRI) 28.60
LZAGY's PE(NRI) is ranked higher than
90% of the 340 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. LZAGY: 28.60 )
LZAGY' s 10-Year PE(NRI) Range
Min: 8.61   Max: 69.7
Current: 28.6

8.61
69.7
P/B 3.30
LZAGY's P/B is ranked higher than
70% of the 340 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.64 vs. LZAGY: 3.30 )
LZAGY' s 10-Year P/B Range
Min: 0.74   Max: 3.97
Current: 3.3

0.74
3.97
P/S 1.91
LZAGY's P/S is ranked higher than
79% of the 340 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.51 vs. LZAGY: 1.91 )
LZAGY' s 10-Year P/S Range
Min: 0.63   Max: 2.58
Current: 1.91

0.63
2.58
PFCF 23.50
LZAGY's PFCF is ranked higher than
91% of the 340 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. LZAGY: 23.50 )
LZAGY' s 10-Year PFCF Range
Min: 6.16   Max: 210.54
Current: 23.5

6.16
210.54
POCF 14.04
LZAGY's POCF is ranked higher than
92% of the 340 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. LZAGY: 14.04 )
LZAGY' s 10-Year POCF Range
Min: 3.47   Max: 36.17
Current: 14.04

3.47
36.17
EV-to-EBIT 20.66
LZAGY's EV-to-EBIT is ranked higher than
89% of the 340 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. LZAGY: 20.66 )
LZAGY' s 10-Year EV-to-EBIT Range
Min: 9.9   Max: 32.6
Current: 20.66

9.9
32.6
PEG 7.94
LZAGY's PEG is ranked higher than
91% of the 340 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. LZAGY: 7.94 )
LZAGY' s 10-Year PEG Range
Min: 0.25   Max: 77.44
Current: 7.94

0.25
77.44
Shiller P/E 37.10
LZAGY's Shiller P/E is ranked higher than
91% of the 340 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. LZAGY: 37.10 )
LZAGY' s 10-Year Shiller P/E Range
Min: 6.25   Max: 37.1
Current: 37.1

6.25
37.1
Current Ratio 1.21
LZAGY's Current Ratio is ranked higher than
52% of the 296 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.52 vs. LZAGY: 1.21 )
LZAGY' s 10-Year Current Ratio Range
Min: 0.97   Max: 1.84
Current: 1.21

0.97
1.84
Quick Ratio 0.63
LZAGY's Quick Ratio is ranked lower than
55% of the 296 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.16 vs. LZAGY: 0.63 )
LZAGY' s 10-Year Quick Ratio Range
Min: 0.62   Max: 1.09
Current: 0.63

0.62
1.09
Days Inventory 78.00
LZAGY's Days Inventory is ranked higher than
79% of the 340 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 141.40 vs. LZAGY: 78.00 )
LZAGY' s 10-Year Days Inventory Range
Min: 95   Max: 123.17
Current: 78

95
123.17
Days Sales Outstanding 62.37
LZAGY's Days Sales Outstanding is ranked higher than
81% of the 340 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 84.80 vs. LZAGY: 62.37 )
LZAGY' s 10-Year Days Sales Outstanding Range
Min: 6.55   Max: 94.23
Current: 62.37

6.55
94.23

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.80
LZAGY's Dividend Yield is ranked higher than
80% of the 91 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.32 vs. LZAGY: 1.80 )
LZAGY' s 10-Year Dividend Yield Range
Min: 0.96   Max: 6.38
Current: 1.8

0.96
6.38
Dividend Payout 0.42
LZAGY's Dividend Payout is ranked higher than
89% of the 340 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. LZAGY: 0.42 )
LZAGY' s 10-Year Dividend Payout Range
Min: 0.22   Max: 1.29
Current: 0.42

0.22
1.29
Yield on cost (5-Year) 2.28
LZAGY's Yield on cost (5-Year) is ranked higher than
74% of the 94 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.47 vs. LZAGY: 2.28 )
LZAGY' s 10-Year Yield on cost (5-Year) Range
Min: 1.21   Max: 8.07
Current: 2.28

1.21
8.07
Share Buyback Rate -0.20
LZAGY's Share Buyback Rate is ranked higher than
87% of the 195 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.60 vs. LZAGY: -0.20 )
LZAGY' s 10-Year Share Buyback Rate Range
Min: 0.6   Max: -3.4
Current: -0.2

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 59.10
LZAGY's Price/Tangible Book is ranked lower than
55% of the 340 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 11.30 vs. LZAGY: 59.10 )
LZAGY' s 10-Year Price/Tangible Book Range
Min: 2.27   Max: 15.87
Current: 59.1

2.27
15.87
Price/DCF (Projected) 2.00
LZAGY's Price/DCF (Projected) is ranked higher than
89% of the 340 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. LZAGY: 2.00 )
LZAGY' s 10-Year Price/DCF (Projected) Range
Min: 1.57   Max: 5.86
Current: 2

1.57
5.86
Price/Median PS Value 1.40
LZAGY's Price/Median PS Value is ranked higher than
64% of the 340 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.30 vs. LZAGY: 1.40 )
LZAGY' s 10-Year Price/Median PS Value Range
Min: 0.45   Max: 1.57
Current: 1.4

0.45
1.57
Price/Graham Number 8.80
LZAGY's Price/Graham Number is ranked higher than
78% of the 340 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. LZAGY: 8.80 )
LZAGY' s 10-Year Price/Graham Number Range
Min: 1.17   Max: 7.21
Current: 8.8

1.17
7.21
Earnings Yield (Greenblatt) 4.60
LZAGY's Earnings Yield (Greenblatt) is ranked higher than
86% of the 296 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.20 vs. LZAGY: 4.60 )
LZAGY' s 10-Year Earnings Yield (Greenblatt) Range
Min: 3.1   Max: 10.1
Current: 4.6

3.1
10.1
Forward Rate of Return (Yacktman) 5.95
LZAGY's Forward Rate of Return (Yacktman) is ranked higher than
67% of the 98 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 11.26 vs. LZAGY: 5.95 )
LZAGY' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -13.3   Max: 38.4
Current: 5.95

-13.3
38.4

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare: » details
Traded in other countries:O6Z.Singapore, 0QNO.UK, LONN.Switzerland, LO3.Germany,
Lonza Group AG was founded in 1897. The Company is a suppliers of biopharmaceuticals to the Pharma&Biotech and Specialty Ingredient markets. Its products and services range from active pharmaceutical ingredients and stem-cell therapies to drinking water sanitizers, from industrial preservatives to microbial control solutions that combat dangerous viruses, bacteria and other pathogens, from the manufacture of vitamin B compounds and organic personal care ingredients to agricultural services and products. The Company operates in two market segments: The Lonza Pharma&Biotech and The Lonza Specialty Ingredients. The Lonza Pharma&Biotech (LPB) market segment clusters all of its offerings for pharmaceutical markets, with strong Lonza positions in Custom Development, Custom Manufacturing and Bioscience Solutions. The Lonza Specialty Ingredients (LSI) market segment includes consumer-oriented offerings, with Consumer Care encompassing its Personal Care & Preservation, Nutrition and Hygiene offerings.
» More Articles for OTCPK:LZAGY

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
Lonza Reports Robust Q1 Performance and Sound Growth Prospects Until 2018 Apr 28 2015
Lonza Consumer Care Takes Active Role at Vitafoods Europe 2015 Apr 22 2015
Lonza Industrial Solutions Offers Europe a New Innovative Preservative for In-Can Preservation Apr 17 2015
in-cosmetics Barcelona 2015: Lonza Showcases Innovations Inspiring Formulators Apr 15 2015
Lonza Consumer Care Introduces Highly Efficacious Geogard® LSA Preservative Blend Apr 10 2015
Lonza Group Ltd Announces Results of Annual General Meeting Apr 08 2015
CPI led UK Biotech consortium secures £6.2m government investment Mar 30 2015
Antibacterial Hand Soaps Formulated with Lonzagard® BKC cGMP Help Reduce the Spread of Germs Mar 26 2015
Lonza Celebrates 30th Anniversary of Carnipure® L-Carnitine: Highlights Continued Scientific... Mar 18 2015
Lonza Publishes Annual Report 2014 and Invitation to the 2015 Annual General Meeting Mar 13 2015
Lonza Consumer Care Announces Appointment of Vito Cataldo to Role of North Mar 12 2015
Lonza Helps Customers Navigate Through EPA’s Quat Data Call In (DCI) Mar 03 2015
Lonza and arGEN-X Announce a Multi-product GS Xceed™ License Agreement for Therapeutic Antibodies Feb 18 2015
TiGenix and Lonza Sign Agreement for the Manufacture of Stem Cell-based Treatment Feb 12 2015
TiGenix and Lonza Sign Agreement for the Manufacture of Stem Cell-based Treatment of Complex... Feb 12 2015
Philip Ludwig, Lonza Joins the Center for Dermal Research (CDR) Advisory Council Feb 03 2015
Lonza Offers Lonzagard® Disinfectants for Flu Virus Infection Prevention and Control Jan 29 2015
Lonza Continues to Make Measurable Progress in Its Transformation Jan 21 2015
Lonza and AdAlta Announce a Strain Development Contract for Novel Biologic Therapeutics Dec 18 2014
Lonza Executes Collaboration Agreements with Two Innovation Clusters Dec 10 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK